Moreover, exposure to carboxypeptidase A, an enzyme found at elevated levels in plasma of individuals with pancreatitis, resulted in cleavage of L585 from the C-terminal end of HSA, also in the approved drug Tanzeum®, and consequently reduced hFcRn binding. This evidence concerns the gene ALB and pancreatitis.